GlobalData on MSN13h
InflaRx wins EU approval for Gohibic in Covid-19-induced ARDSThe European Commission (EC) has granted marketing authorisation under exceptional circumstances for InflaRx’s Gohibic ...
H.C. Wainwright analyst Edward White reiterated a Buy rating on InflaRx (IFRX – Research Report) today and set a price target of $8.00.Stay ...
InflaRx (IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients ...
Hosted on MSN12h
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 DrugInflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...
InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the ...
H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:IFRX), following the European ...
JENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today ...
CEO Kristian Teär has purchased shares in the period 10 January to 14 January 2025, which as of 13 January 2025 exceeded the reporting limit of EUR 20,000. As of 14 January 2025, Kristian Teär has ...
After hours: January 14 at 4:42:21 p.m. EST ...
At close: January 13 at 4:00:01 p.m. EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback